Kaveri Pohlman
Stock Analyst at Clear Street
(2.02)
# 3,126
Out of 5,105 analysts
31
Total ratings
40.62%
Success rate
-3.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $67.22 | +47.28% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $96.78 | +106.65% | 1 | Dec 5, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $80 → $32 | $15.21 | +110.39% | 2 | Dec 2, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $14.83 | +68.58% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $13.29 | +58.01% | 1 | Nov 14, 2025 | |
| ZURA Zura Bio | Initiates: Buy | $18 | $4.02 | +347.76% | 1 | Nov 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $29 | $6.33 | +358.14% | 1 | Oct 22, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $41 → $60 | $36.72 | +63.40% | 2 | Oct 21, 2025 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $8.24 | +33.50% | 1 | Oct 1, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $29.94 | +53.64% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $24.29 | +31.77% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $31.54 | +49.02% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $12.63 | +137.53% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $16.78 | +126.46% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $8.45 | -40.83% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.30 | +86.05% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $40.91 | -33.99% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $22.67 | +208.78% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.15 | +280.95% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.12 | +94.17% | 2 | Jul 7, 2022 |
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $67.22
Upside: +47.28%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $96.78
Upside: +106.65%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $80 → $32
Current: $15.21
Upside: +110.39%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $14.83
Upside: +68.58%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $13.29
Upside: +58.01%
Zura Bio
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $4.02
Upside: +347.76%
Sagimet Biosciences
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $6.33
Upside: +358.14%
RAPT Therapeutics
Oct 21, 2025
Maintains: Buy
Price Target: $41 → $60
Current: $36.72
Upside: +63.40%
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $8.24
Upside: +33.50%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $29.94
Upside: +53.64%
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $24.29
Upside: +31.77%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $31.54
Upside: +49.02%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $12.63
Upside: +137.53%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $16.78
Upside: +126.46%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $8.45
Upside: -40.83%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $4.30
Upside: +86.05%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $40.91
Upside: -33.99%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $22.67
Upside: +208.78%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $3.15
Upside: +280.95%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.12
Upside: +94.17%